Infectious disease experts are dismayed by a change in how young children are protected against respiratory syncytial virus (RSV). A monoclonal antibody against RSV for infants is considered a major public health advance. This antibody has been reduced for vaccination of children. The article questions whether this progress in conservation will be reversed.